(0.35%) 5 117.83 points
(0.34%) 38 368 points
(0.38%) 15 989 points
(-0.95%) $83.05
(5.51%) $2.03
(0.33%) $2 355.00
(0.45%) $27.66
(4.09%) $959.80
(-0.26%) $0.932
(-0.41%) $10.98
(-0.56%) $0.796
(1.66%) $93.40
@ $1.280
発行日: 14 2月 2024 @ 23:35
リターン: -7.81%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 11.20 %
Live Chart Being Loaded With Signals
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom...
Stats | |
---|---|
本日の出来高 | 744 758 |
平均出来高 | 2.06M |
時価総額 | 268.06M |
EPS | $0 ( 2024-03-04 ) |
次の収益日 | ( $-0.160 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.19 |
ATR14 | $0.00500 (0.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-08 | Ecor1 Capital, Llc | Buy | 0 | Ordinary Shares |
2024-03-18 | Piccina Cintia | Buy | 5 088 864 | Option to purchase Ordinary Shares |
2024-03-18 | Piccina Cintia | Buy | 1 130 832 | Option to purchase Ordinary Shares |
2024-01-17 | Rawcliffe Adrian | Sell | 30 080 | American Depositary Shares representing Ordinary Shares |
2024-01-16 | Rawcliffe Adrian | Sell | 9 304 | American Depositary Shares representing Ordinary Shares |
INSIDER POWER |
---|
96.16 |
Last 96 transactions |
Buy: 71 750 188 | Sell: 1 254 319 |
ボリューム 相関
Adaptimmune Therapeutics 相関
10 最も正の相関 | |
---|---|
ASLN | 0.967 |
FBRX | 0.966 |
CLPT | 0.966 |
AGRX | 0.964 |
VLCN | 0.963 |
SOFO | 0.961 |
SCPH | 0.961 |
TELA | 0.959 |
SVRE | 0.958 |
ESTA | 0.958 |
10 最も負の相関 | |
---|---|
ADV | -0.976 |
MLAI | -0.97 |
RCMT | -0.969 |
NVSA | -0.967 |
MPRA | -0.965 |
SVRA | -0.965 |
SCOB | -0.964 |
KAII | -0.964 |
STCN | -0.964 |
BTWN | -0.963 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Adaptimmune Therapeutics 相関 - 通貨/商品
Adaptimmune Therapeutics 財務諸表
Annual | 2023 |
収益: | $60.51M |
総利益: | $50.66M (83.71 %) |
EPS: | $-0.570 |
FY | 2023 |
収益: | $60.51M |
総利益: | $50.66M (83.71 %) |
EPS: | $-0.570 |
FY | 2022 |
収益: | $27.15M |
総利益: | $-100.58M (-370.48 %) |
EPS: | $-1.030 |
FY | 2021 |
収益: | $6.15M |
総利益: | $6.15M (100.00 %) |
EPS: | $-1.020 |
Financial Reports:
No articles found.
Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。